English

Year-end report - 2003

Report this content

Year-end report - 2003 An important year for Biolipox - International venture-capital companies invest SEK 190 million - Clinical phase I study successfully concluded - phase II study initiated - Strengthened - and expanded - project portfolio - Stronger focus on research operations through establishment of an in-house research unit at the Karolinska Institutet - Large increase in number of chemists - intensified search for drug candidates - Biolipox extend cooperation in drug development - Torbjörn Bjerke assumes position as President & CEO - Håkan Åström elected Chairman of the Board - Net sales amounted to SEK 0 (0) - Result after tax amounted to a loss of SEK 63.3 million (loss 35.7) - Earnings per share amounted to a loss of SEK 72.46 (loss 37.70) For further information, please contact: Torbjörn Bjerke, President & CEO, Tel: + 46 (0)70-66 19 90, e-mail: torbjorn.bjerke@biolipox.com Jarl Molin, VP Communications/Business Development, Tel: +46 (0)8-545 281 47, Mobile: 46(0)70-560 2056, e-mail: jarl.molin@biolipox.com. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/01/18/20040511BIT21080/wkr0006.pdf The full report

Documents & Links